Company Filing History:
1 out of 26 
1 out of 61 
Years Active: 2016
Title: Adrian Zürcher: Innovator in CD89 Activation Therapy
Introduction
Adrian Zürcher is a notable inventor based in Bern, Switzerland. He has made significant contributions to the field of immunology, particularly through his innovative work on CD89 activation in therapy. His research focuses on the therapeutic potential of CD89 activating molecules, which have implications for treating various disorders.
Latest Patents
Adrian Zürcher holds 1 patent related to his groundbreaking work. His patent, titled "CD89 activation in therapy," describes the use of CD89 activating molecules, especially those comprising Fc alpha, such as IgA, to induce apoptosis in neutrophils. This activation is particularly beneficial in treating disorders associated with increased neutrophils, including autoimmune disorders, inflammatory disorders, NETosis, and cystic fibrosis. Additionally, anti-CD89 antibodies can be utilized as an alternative therapeutic approach.
Career Highlights
Throughout his career, Zürcher has worked with prominent organizations, including CSL Behring AG and Universität Bern. His experience in these institutions has allowed him to advance his research and contribute to the scientific community significantly.
Collaborations
Adrian Zürcher has collaborated with esteemed colleagues, including Stephan Von Gunten and Marc Wehrli. These partnerships have enriched his research and fostered innovation in the field of immunology.
Conclusion
Adrian Zürcher's work in CD89 activation therapy exemplifies the impact of innovative research on medical treatments. His contributions continue to pave the way for advancements in therapies for various disorders.